Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing
Clinical trial NCT03608865 · COMPLETED
Trial details
- NCT number
- NCT03608865
- Sponsor
- Yonsei University
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-19
- Primary completion
- 2021-11-24
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.